Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2005-06-07
2005-06-07
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S177100, C424S179100, C424S451000, C424S470000, C424S482000, C424S490000
Reexamination Certificate
active
06902743
ABSTRACT:
Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer having a molar composition of lactide/glycolide from 90/10 to 40/60, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging to ratios from 100/0 to 1/99.
REFERENCES:
patent: 3540444 (1970-11-01), Moreland
patent: 3788315 (1974-01-01), Laurens
patent: 4166800 (1979-09-01), Fong
patent: 4384975 (1983-05-01), Fong
patent: 4530840 (1985-07-01), Tice et al.
patent: 4542025 (1985-09-01), Tice et al.
patent: 4585482 (1986-04-01), Tice et al.
patent: 4622244 (1986-11-01), Lapka et al.
patent: 4637905 (1987-01-01), Gardner
patent: 4675189 (1987-06-01), Kent et al.
patent: 4798786 (1989-01-01), Tice et al.
patent: 4835139 (1989-05-01), Tice et al.
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4938763 (1990-07-01), Dunn et al.
patent: 4941880 (1990-07-01), Burns
patent: 5000886 (1991-03-01), Lawter et al.
patent: 5019096 (1991-05-01), Fox, Jr. et al.
patent: 5059187 (1991-10-01), Sperry et al.
patent: 5064413 (1991-11-01), McKinnon et al.
patent: 5075109 (1991-12-01), Tice et al.
patent: 5102872 (1992-04-01), Singh et al.
patent: 5129825 (1992-07-01), Discko, Jr.
patent: 5133701 (1992-07-01), Han
patent: 5236355 (1993-08-01), Brizzolara et al.
patent: 5278202 (1994-01-01), Dunn et al.
patent: 5290494 (1994-03-01), Coombes et al.
patent: 5360610 (1994-11-01), Tice et al.
patent: 5384133 (1995-01-01), Boyes et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5417986 (1995-05-01), Reid et al.
patent: 5429822 (1995-07-01), Gresser et al.
patent: 5500228 (1996-03-01), Lawter et al.
patent: 5538739 (1996-07-01), Bodmer et al.
patent: 5639480 (1997-06-01), Bodmer et al.
patent: 5643605 (1997-07-01), Cleland et al.
patent: 5648096 (1997-07-01), Gander et al.
patent: 5650173 (1997-07-01), Ramstack et al.
patent: 5688530 (1997-11-01), Bodmer et al.
patent: 5693343 (1997-12-01), Reid et al.
patent: 5762965 (1998-06-01), Burnett et al.
patent: 5811128 (1998-09-01), Tice et al.
patent: 5814344 (1998-09-01), Tice et al.
patent: 5820883 (1998-10-01), Tice et al.
patent: 5853763 (1998-12-01), Tice et al.
patent: 6447796 (2002-09-01), Vook et al.
patent: 0052510 (1994-10-01), None
Gilding, Biodegradable polymers for use in surgery-polyglycolic/poly (ac c acid) homo- and copolymers: 1, Polymer, vol. 20, Dec. 1979, pp1459-1464.
Biotechnology News, Aug. 22, 1997, vol. 17, No. 20, Topical DNA vaccine elicits immune response.
Hall, et al., Purification and Analysis of Colonization Factor Antigen I,ColiSurface Antigen 1, andColiSurface Antigen 3 Fimbriae from EnterotoxigenicEscherichia Coli, Journal of Bacteriology, Nov. 1989, p6372-6374, vol. 171, No. 11.
Evans, et al. Purification and Characterization of the CFR/I Antigen of EnterotoxigenicEscherichia coli, Infection and Immunity, Aug. 1979, p 738-748, vol. 25.
Karjalainen, et al., Molecular Cloning and Nucleotide Sequence of the Colonization Factor Antigen I Gene ofEscherichia coli, Infection and Immunity, Apr. 1989, p1126-1130, vol. 57.
Jeyanthi, et al., Novel, Burst Free Programmable Biodegradable Microspheres For Controlled Release of Polypeptides, Proceedings Int. Symp. control Release Bioact. Mater. (1996) p351-3521.
Yeh, A novel emulsification-solvent extraction technique for production of potein loaded biodegradable microparticles for vaccine and drug delivery, Journal of Controlled Release, 33 (1005) 437-445. (1990).
Yan, Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by watewr-in-oil-in-water emulsion technique, Journal of Controlled Release, 32 (1994) 231-241.
Wang, et al., Influence of formulation methods on the in vitro controlled release of protien from poly (ester) microspheres Journal of Controlled Release, 17 (1991) 23-32.
Brown, Wonder Drugs' Losing Healing Aura, The Washing Post, Jun. 26, 1995, A section.
Setterstrom, Controlled Release of Antibiotics From biodegradable Microcapsules For Wound infection Control, Chemical Abstracts, 1983, pp215-226.
Perez-Casal, et al., Gene Encoding the Major Subunit of CS1 Pili of Human EnterotoxigenicEscherichia Coli, Infection and Immunity, Nov., 1990, p 3594-3600, vol. 58, No. 11.
Jordi, et al., Analysis of the first two genes of the CS1 fimbrial operon in human enterotoxigenicEscherichia coliof serotype 0139: H28, FEMS Microbiology Letters 80, (1991) p265-270.
Tan, et al., Mapping the Antigenic Epitopes of Human Dihydrofolate Reductase by Systematic Synthesis of Peptides on soid Supports, The Journal of Biological Chemistry, vol. 265, No. 14, Issue of May 15, pp. 8022-8026 (1990).
McConnel, et al., Antigenic homology within human enterotoxigenicEsherichia colifimbrial colonization factor antigens: CFA/I, coli-surface-associated antigens (CS)1, CS2, CS4 and CS17, FEMS Microbiology Letters 61 (1989) 105-108.
Van der Zee, Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides, Eur. J. Immunol. 1989, 19: 43-47.
Cassels, et al., Analysis ofEscherichia coliColonization Factor AntigenI Linear B-Cell Epitopes, as Determined by Primate Responses, following Protein Sequence Verification, Infection and Immunity, Jun. 1992, p. 2174-2181, vol. 60, No. 6.
Romagnoli, et al. Peptide-MHC Interaction: A Rational Approach to Vaccine Design, Inter, RE. Immunol. 6, 1990, 004 61-73.
Maister, First Oral AIDS Vaccine Trials Near, BioWorld Today, Tuesday, Apr. 19, 1994, p. 4.
Rognan, et al., Molecular Modeling of an Antigenic Complex Between a Viral Peptide and a Class I Major Histocompatibility Glycoprotein, Proteins Structure, Function and Genetics 13 70-85 (1992).
Brown, A hypothetical model of the foreign antigen biinding site of Class II histocompatibility molecules, Nature, vol. 332, Apr. 28, 1988, p845-850.
Bhattacharjee Apurba
Boedecker Edgar C.
Cross Alan
Friden Phil
Jacob Elliot
Arwine Elizabeth
Criares Theodore J.
Harris Charles H.
Moran John Francis
The United States of America as represented by the Secretary of
LandOfFree
Therapeutic treatment and prevention of infections with a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic treatment and prevention of infections with a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment and prevention of infections with a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3509662